Table 1 Clinical and demographic characteristics at baseline

Age, years, mean (SD)

(8.8)

Female, n (%)

(54.3)

Education, years, mean (SD)

(3.6)

Drugs in regular use, mean (SD)

(2.6)

 Antihypertensives, number of users (%)

(48.9)

 Statins, number of users (%)

(14.7)

 Antidiabetic agents (number of users, %)

(7.1)

 Antithrombotic agents (number of users, %)

(46.8)

  Platelet inhibitors (number of users, %)

(40.4)

  Anticoagulants (number of users, %)

(7.5)

ApoE ε4 carrier, n (%)

(61.1)

MMSE (0–30), mean (SD)

(4.4)

CDR sum of boxes (0–18), mean (SD)

(2.8)

 Hypertension, n (%)

(83.0)

 Hypercholesterolemia, n (%)

(52.8)

 Diabetes mellitus, n (%)

(9.2)

 Overweight (BMI > 25), n (%)

(41.4)

 Smoking (current), n (%)

(9.5)

Framingham Stroke Risk Profile^b (0–1), women, mean (SD)

(0.14)

Framingham Stroke Risk Profile^b (0–1), men, mean (SD)

(0.16)

 Atrial fibrillation, n (%)

(9.9)

 History of cerebrovascular event (stroke or TIA), n (%)

(15.2)

 History of heart disease, n (%)

(16.3)

 Left ventricular hypertrophy in ECG^a, n (%)

(3.8)

 History of peripheral vascular disease, n (%)

(2.6)

 Estimated GFR < 60 ml/min/1.73m², n (%)

(17.2)

Medial temporal lobe atrophy (mean of both sides), mean (SD)

(0.9)

Cortical infarcts, n (%)

(4.4)

Lacunar infarcts, n (%)

(16.0)

 Fazekas 0 or 1, n (%)

(40.9)

 Fazekas 2, n (%)

(25.9)

 Fazekas 3, n (%)

(33.2)

Cerebrovascular disease: cortical infarcts, lacunes or Fazekas ≥2, n

(62.1)

Cerebrovascular disease: cortical infarcts, lacunes or Fazekas 3, n

(42.7)